Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

  1. Ciruelos, E.
  2. Alba, E.
  3. López, R.
  4. Lluch, A.
  5. Martín, M.
  6. Arroyo, I.
  7. Navarro, B.
  8. Carcedo, D.
  9. Colomer, R.
  10. Albanell, J.
Revista:
Oncotarget

ISSN: 1949-2553

Ano de publicación: 2019

Volume: 10

Número: 42

Páxinas: 4321-4332

Tipo: Artigo